Director - Clinical Development Oncology - Global Medical Affairs
Since March 2015
I have become part of Novartis Oncology following the completion of the recent purchase of GSK Oncology by Novartis. I continue to support Votrient (Pazopanib) for both RCC & STS indications
Director - Oncology Global Medical Affairs
January 2012 --- March 2015
Member of the Votrient Global Medical Team supporting global medical activities for the soft tissue sarcoma indication. I also support Votrient medical teams for Asia Pac / Emerging Markets / Japan.
Director / Clinical Leader
September 2006 --- January 2012
Votrient™ (Pazopanib) Clinical indication leader for Sarcoma and clinical lead for the Phase III (PALETTE) study team. The successful Phase III study was recently published in the Lancet - http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60651-5/abstract Throughout 2009 I worked for Oncology R&D in the APJEM (Asia Pacific - Japan - Emerging Markets) team, and returned to PALETTE team in 2010.
Director/Clinical Leader - Oncology
May 2001 --- September 2006
Clinical Leader for 2 of Pfizer's oncology development programmes.
Associate Director - International Clinical Research
December 1999 --- May 2001
Managed Global studies (ex-US) for Agouron in oncology & HIV. Head of Agouron's UK clinical operation
Senior Clinical Manager - Oncology & Biotherapeutics
January 1997 --- January 1999
Contract research house: Managed oncology development programmes on behalf of clients (worked extensively with Japanese Pharma).
Oncology Group Leader
January 1995 --- January 1997
January 1990 --- January 1995
M.Sc in Chemistry (Analytical Toxicology & Pharmacology) from University of Greenwich in 1988
in from Bedford School in 1977